信达生物涨7.421%，泡泡玛特涨5.757%，紫金矿业涨5.575%，中国平安涨4.885%，中芯国际涨 4.068%，中国人寿涨3.976%，京东健康涨3.888%。 本文源自：金融界AI电报 ...

2月9日，港股市场迎来久违的"逼空"行情，三大指数高开高走，延续强势反弹势头，截止收盘，港股恒 生指数涨1.76%报27027.16点，恒生科技指数涨1.34%报5417.6点，国企指数涨1.52%报9168.33点，红筹 指数涨0.8%报4395.49点。 2. 资源与能源：供需缺口逻辑中广核矿业（01164）大涨超8%。华西证券指出，全球一次铀供应缺口将 依赖复产项目，而哈原工与关西电力的签约或加剧供需紧张，作为中广核集团海外唯一铀资源平台，其 龙头地位凸显。稀土永磁板块走强，金力永磁（06680）涨4.72%。受分离厂停产及大厂补库影响，氧 化镨钕价格跳涨至80.5万元/吨，市场看涨情绪升温。 3. 机器人与高端制造：全球龙头效应卧安机器人（06600）飙升近12%。作为2024年全球家庭机器人系 统零售额冠军（市占率11.9%），且有望在2026年3月纳入港股通，其稀缺性备受瞩目。迈富时 （02556）涨超7%，Agent需求的指数级爆发是其核心催化剂。 4. 消费与文娱：IP与新品驱动泡泡玛特（09992）涨5%，延续强势。心动公司（02400）涨4.23%，旗下 《心动小镇》凭借"小马宝莉"IP联 ...

2026 年 02 月 09 日 王睿哲 C0062@capital.com.tw 目标价(港币) 98 公司基本资讯 | 产业别 | | 医药生物 | | --- | --- | --- | | H 股价(2026/02/06) | | 79.50 | | 恒生指数(2026/02/06) | | 26560.00 | | 股价 12 个月高/低 | | 107.00 / 33.05 | | 总发行股数(百万) | | 1735.19 | | H 股数(百万) | | 1735.19 | | H 市值(亿港币) | | 1379.47 | | 主要股东 | | 俞德超(5.36%) | | 每股净值(港币) | | 9.8324 | | 股价/帐面净值 | | 8.0855 | | | 一个月 三个月 | 一年 | | 股价涨跌(%) | -10.97 -6.69 139.82 | | 近期评等 | 出刊日期 | 前日收盘 | 评等 | | --- | --- | --- | | 2025/10/22 | 88.00 | 买进 | | 产品组合 | | | --- | --- | | 药品销售 | 87% ...

Investment Rating - The report assigns an "Outperform" rating for the pharmaceutical sector, indicating a positive outlook compared to the broader market [2][4]. Core Insights - The collaboration between Innovent Biologics and Eli Lilly has been upgraded, aiming to create a global innovative ecosystem for drug development in oncology and immunology. This partnership marks their seventh collaboration, enhancing their strategic relationship over more than a decade [2]. - The Chinese government has introduced a high-quality development plan for traditional Chinese medicine (TCM), focusing on improving raw material supply, innovation, and manufacturing capabilities. The plan aims to establish a collaborative development system by 2030, with significant investments in TCM innovation [2]. Summary by Sections Market Performance - The SW Pharmaceutical Biotechnology Index increased by 0.14% during the week of February 2 to February 8, outperforming the CSI 300 Index, which decreased by 1.33%. The Chinese medicine sector saw a notable rise of 2.56% due to new policies, while vaccines and other bioproducts experienced declines [2]. Strategic Collaborations - Innovent Biologics and Eli Lilly's new agreement includes a $350 million upfront payment and potential milestone payments of up to $8.5 billion, along with a tiered sales revenue sharing model for products outside Greater China. This partnership signifies a shift from traditional licensing to deeper integration of technology platforms and R&D systems [2]. Investment Opportunities - The report highlights continued optimism for Chinese innovative drugs entering international markets, particularly in areas such as antibody-drug conjugates (ADCs), dual antibodies, small nucleic acids, and weight-loss medications. Key companies to watch include Innovent Biologics, 3SBio, WuXi AppTec, and others [2].

Core Insights - Chinese innovative biopharmaceutical company Innovent Biologics (01801.HK) has announced a global strategic collaboration with Eli Lilly to advance the global development of innovative drugs in oncology and immunology, marking their seventh collaboration since 2015 [1][3] Group 1: Collaboration Details - The partnership aims to leverage complementary strengths to accelerate the global development of innovative drugs, with Innovent leading the research from drug discovery to clinical concept verification in China, while Eli Lilly will have exclusive global development and commercialization rights outside Greater China [3] - Innovent will receive an upfront payment of $350 million, with potential milestone payments totaling up to $8.5 billion if all development, regulatory, and commercialization milestones are achieved [3] Group 2: Financial Performance and Market Position - Innovent has established a high-quality technology platform covering the entire cycle of biopharmaceutical development, with 18 products approved for market, 4 new drug molecules in Phase III or pivotal clinical studies, and 15 new drug candidates in clinical research [4] - Recent revenue forecasts indicate that Innovent expects approximately 11.9 billion yuan in product revenue for 2025, representing a 45% year-on-year increase, with Q4 revenue projected at around 3.3 billion yuan, showing over 60% growth year-on-year [4] - The collaboration with Eli Lilly further solidifies Innovent's position in the global innovative drug sector, following a previous $11.2 billion partnership with Takeda in October 2025 [4]

研究报告 Research Report 9 Feb 2026 香港医疗 Hong Kong Health Care 医药行业周报（2026.02.02-2026.02.06）：市场情绪回暖；看好基本面表现强劲的创新药产业链龙头 Healthcare Weekly (2026.02.02-2026.02.06): Market Sentiment Warms; Bullish on Leaders in Innovative Drug Chain with Strong Fundamentals [Table_yemei1] 观点聚焦 Investment Focus | [Table_Info] | | | | | --- | --- | --- | --- | | 股票名称 | 评级 | 股票名称 | 评级 | | 百济神州 | Outperform 华润医药 | | Outperform | | 京东健康 | Outperform 国药控股 | | Neutral | | 药明生物 | Outperform 映恩生物 | | Outperform | | 信达生物 | Outperform 金斯瑞生物科 ...

Group 1: Bubble Mart (泡泡玛特) - Citic Jiantou maintains an "Accumulate" rating for Bubble Mart, highlighting the company's "one strong, multiple strong" IP structure, with Labubu's influence solidified and new IPs like Xingxingren and Crybaby driving high growth [1] Group 2: MGM China (美高梅中国) - Haitong International maintains a "Buy" rating for MGM China, reporting a 21.4% year-on-year increase in total revenue for Q4 2025, with adjusted EBITDA rising 29.5% to HKD 2.75 billion, driven by strong performance from MGM Cotai and precise targeting of high-end customers [2] - CICC also maintains an "Outperform" rating for MGM China, noting adjusted EBITDA of HKD 2.753 billion for Q4 2025, up 29% year-on-year, significantly exceeding market expectations, despite a brand fee increase expected to impact net profit by about 14% [4] - Citic Securities maintains an "Accumulate" rating for MGM China, indicating that the company's performance exceeded expectations, with net income and adjusted EBITDA recovering to pre-pandemic levels, supported by strong performances from MGM Macau and MGM Cotai [7] Group 3: Yum China (百胜中国) - Haitong International maintains a "Buy" rating for Yum China, reporting a 9% year-on-year revenue increase for Q4 2025 and a 24% increase in adjusted net profit, with same-store sales growing for three consecutive quarters and restaurant profit margins improving by 0.7 percentage points to 13.0% [3] Group 4: Innovent Biologics (信达生物) - CICC maintains an "Outperform" rating for Innovent Biologics, projecting product revenue of RMB 11.9 billion for 2025, a 45% year-on-year increase, with seven new products included in the 2026 medical insurance catalog [5] Group 5: Swire Properties (太古地产) - CICC maintains an "Outperform" rating for Swire Properties, noting significant recovery in luxury retail operations in mainland China, with retail sales in Shanghai and Beijing increasing by 49.6% and 11.2% respectively [6] Group 6: Meituan (美团) - Citic Securities maintains a "Buy" rating for Meituan, announcing a plan to acquire Dingdong Maicai for USD 717 million, which is expected to strengthen its East China front warehouse network and bring in HKD 170 million in adjusted net profit post-integration [8] Group 7: Kuaishou (快手) - Citic Jiantou maintains a "Buy" rating for Kuaishou, highlighting the launch of its AI video model 3.0, which supports 15-second generation and intelligent scene segmentation, with commercial growth expected to reach USD 240 million in ARR by 2025 [10] Group 8: Huiju Technology (汇聚科技) - Citic Jiantou maintains a "Buy" rating for Huiju Technology, emphasizing its deep ties with leading CSPs like Google and the benefits from the upgrade of optical modules, projecting a revenue increase of 82.1% year-on-year for H1 2025 [10]

高盛相信，信达生物将继续保持其在中国生物技术领域的领先地位，主要得益于拥有大量针对下一代免 疫肿瘤靶点的新型分子，并已获得令人鼓舞的初步数据(如IBI363(PD-1/IL-2α偏向性双特异性抗体)，在 免疫治疗/冷肿瘤中具有差异化的药物特性；强大的商业化能力及与全球合作伙伴，特别是礼来公司的 深度合作等。 智通财经APP获悉，高盛发布研报称，信达生物(01801)昨日(8日)宣布与礼来(LLY.US)美元的里程碑付 款；及基于中国以外地区净销售额的分级销售特许权使用费。高盛考虑到当前市场隐含的加权平均资本 成本(12%)较高，认为其目前股价被低估；予该股"买入"评级；基于风险调整后、现金流量折现法，予 目标价102.85港元。 ...

2026 年 02 月 09 日 王睿哲 C0062@capital.com.tw 目标价(港币) 98 近期评等 | 出刊日期 | 前日收盘 | 评等 | | --- | --- | --- | | 2025/10/22 | 88.00 | 买进 | | 产品组合 | | | --- | --- | | 药品销售 | 87% | | 企业授权产品 | 12% | | 研发收入 | 1% | 股价相对大盘走势 C o m p a n y U p d a t e C h i n a R e s e a r c h D e p t . 信达生物 (01801.HK) 买进（Buy） 公司基本资讯 | 产业别 | | 医药生物 | | --- | --- | --- | | H 股价(2026/02/06) | | 79.50 | | 恒生指数(2026/02/06) | | 26560.00 | | 股价 12 个月高/低 | | 107.00 / 33.05 | | 总发行股数(百万) | | 1735.19 | | H 股数(百万) | | 1735.19 | | H 市值(亿港币) | | 1379.47 ...

Group 1 - The Hang Seng Index and the Hang Seng Tech Index both rose over 2% in the afternoon session [1] - Pop Mart (09992.HK) saw an increase of nearly 7% [1] - Innovent Biologics (01801.HK) rose by 6.4% [1] - Zijin Mining (02899.HK) experienced a rise of over 5% [1]